JP2021517587A - 腫瘍浸潤リンパ球(tils)を活性化する方法 - Google Patents

腫瘍浸潤リンパ球(tils)を活性化する方法 Download PDF

Info

Publication number
JP2021517587A
JP2021517587A JP2020557373A JP2020557373A JP2021517587A JP 2021517587 A JP2021517587 A JP 2021517587A JP 2020557373 A JP2020557373 A JP 2020557373A JP 2020557373 A JP2020557373 A JP 2020557373A JP 2021517587 A JP2021517587 A JP 2021517587A
Authority
JP
Japan
Prior art keywords
tumor
cancer
til
subject
fermentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020557373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517587A5 (cg-RX-API-DMAC7.html
Inventor
ルゥ・クン−ミン
クオ・ミン−リャン
ヤン・アイ−ジェン
Original Assignee
マイクロバイオ カンパニー, リミテッド
マイクロバイオ カンパニー, リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイクロバイオ カンパニー, リミテッド, マイクロバイオ カンパニー, リミテッド filed Critical マイクロバイオ カンパニー, リミテッド
Publication of JP2021517587A publication Critical patent/JP2021517587A/ja
Publication of JP2021517587A5 publication Critical patent/JP2021517587A5/ja
Priority to JP2024000217A priority Critical patent/JP2024050573A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2020557373A 2018-01-09 2019-01-09 腫瘍浸潤リンパ球(tils)を活性化する方法 Pending JP2021517587A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000217A JP2024050573A (ja) 2018-01-09 2024-01-04 腫瘍浸潤リンパ球(tils)を活性化する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615300P 2018-01-09 2018-01-09
US62/615,300 2018-01-09
PCT/CN2019/070944 WO2019137384A1 (en) 2018-01-09 2019-01-09 Method of activating tumor-infiltrating lymphocytes (tils)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000217A Division JP2024050573A (ja) 2018-01-09 2024-01-04 腫瘍浸潤リンパ球(tils)を活性化する方法

Publications (2)

Publication Number Publication Date
JP2021517587A true JP2021517587A (ja) 2021-07-26
JP2021517587A5 JP2021517587A5 (cg-RX-API-DMAC7.html) 2022-01-11

Family

ID=67139037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557373A Pending JP2021517587A (ja) 2018-01-09 2019-01-09 腫瘍浸潤リンパ球(tils)を活性化する方法
JP2024000217A Pending JP2024050573A (ja) 2018-01-09 2024-01-04 腫瘍浸潤リンパ球(tils)を活性化する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000217A Pending JP2024050573A (ja) 2018-01-09 2024-01-04 腫瘍浸潤リンパ球(tils)を活性化する方法

Country Status (6)

Country Link
US (1) US11179425B2 (cg-RX-API-DMAC7.html)
EP (2) EP3737395A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021517587A (cg-RX-API-DMAC7.html)
CN (1) CN111655272A (cg-RX-API-DMAC7.html)
TW (1) TWI817977B (cg-RX-API-DMAC7.html)
WO (1) WO2019137384A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019240218A1 (ja) * 2018-06-14 2021-07-01 株式会社明治 免疫チェックポイント阻害療法を促進するための組成物
WO2024057892A1 (ja) 2022-09-12 2024-03-21 賢一郎 蓮見 抗腫瘍免疫応答増強剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003026582A (ja) * 2001-03-21 2003-01-29 Microbio Co Ltd 癌の抑制、感染症の低下、および健康の促進に用いる組成物
WO2017167213A1 (en) * 2016-03-30 2017-10-05 Microbio Co., Ltd. Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134386D1 (de) 2001-03-21 2008-07-24 Microbio Co Ltd Verfahren zur Hemmung von Krebswachstum mit einem fermentierten Soja- Extrakt
JP2003335695A (ja) * 2002-05-17 2003-11-25 Nippon Bio Kk 大豆発酵物よりなる免疫増強剤、抗腫瘍剤、加工食品および大豆発酵物の製造方法
TWI252759B (en) 2002-07-05 2006-04-11 Microbio Co Ltd Method of using fermented glycine max (L.) extract for enhancing natural killer cell activity
CN100352459C (zh) 2004-07-15 2007-12-05 中天生物科技股份有限公司 发酵大豆萃取液在制备药物中的应用
SG187554A1 (en) 2010-07-20 2013-03-28 Microbio Co Ltd Use of a fermented soy extract for manufacture of a prebiotic composition
EP2659898B1 (en) * 2010-12-28 2018-03-07 Kirin Holdings Kabushiki Kaisha Use of lactococcus bacteria in the treatment or prevention of viral infections
JP2015051970A (ja) 2013-09-06 2015-03-19 マイクロバイオ カンパニー, リミテッド 化学療法を受けているがん患者向けのアジュバントを製造するための組成物
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
EP3228701A1 (en) * 2016-04-05 2017-10-11 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
CN112779217B (zh) * 2021-03-29 2023-04-11 复旦大学附属中山医院 一种高记忆表型肿瘤浸润t淋巴细胞的培养方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003026582A (ja) * 2001-03-21 2003-01-29 Microbio Co Ltd 癌の抑制、感染症の低下、および健康の促進に用いる組成物
WO2017167213A1 (en) * 2016-03-30 2017-10-05 Microbio Co., Ltd. Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIVAN, A. ET AL.: "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", SCIENCE, vol. 350, no. 6264, JPN6022051734, 2015, pages 1084 - 1089, ISSN: 0004937805 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019240218A1 (ja) * 2018-06-14 2021-07-01 株式会社明治 免疫チェックポイント阻害療法を促進するための組成物
US11759485B2 (en) 2018-06-14 2023-09-19 Meiji Co., Ltd. Composition for enhancing immune checkpoint blockade therapy
JP7490554B2 (ja) 2018-06-14 2024-05-27 株式会社明治 免疫チェックポイント阻害療法を促進するための組成物
WO2024057892A1 (ja) 2022-09-12 2024-03-21 賢一郎 蓮見 抗腫瘍免疫応答増強剤

Also Published As

Publication number Publication date
EP3737395A4 (en) 2021-09-29
US11179425B2 (en) 2021-11-23
TW201938181A (zh) 2019-10-01
CN111655272A (zh) 2020-09-11
EP4755455A2 (en) 2026-06-10
TWI817977B (zh) 2023-10-11
EP3737395A1 (en) 2020-11-18
US20190209623A1 (en) 2019-07-11
JP2024050573A (ja) 2024-04-10
WO2019137384A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
TWI791111B (zh) 具有預防或治療癌症的效果的新穎菌株
JP7594826B2 (ja) ラクトバチルス・プランタルムgb104株及びそれを含むがんの予防又は処置のための組成物
US12186350B2 (en) Antitumor effect potentiator
Marinelli et al. Probiotic species in the modulation of the anticancer immune response
EP3444332A1 (en) Medium addition kit for culturing nk cells and nk cell culturing method using kit
CN109966320B (zh) 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
CN106148282B (zh) 一种自然杀伤细胞的培养方法
CN109771445B (zh) 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
JP2024050573A (ja) 腫瘍浸潤リンパ球(tils)を活性化する方法
CN112334141B (zh) 用于促进免疫检查点抑制疗法的组合物
CN116421630A (zh) 一种防治肿瘤的嗜粘蛋白阿克曼氏菌产品及其应用
JP7628958B2 (ja) T細胞機能を向上させるための組成物及び方法
CN115806893B (zh) 普通拟杆菌及其组合物在辅助癌症免疫治疗中的应用
CN117503802A (zh) Ac菌在抗肿瘤免疫治疗中的应用
KR102881730B1 (ko) 항암 활성을 갖는 신규 박테리아 균주 및 이를 이용한 암의 완화, 예방 또는 치료용 조성물
TWI847370B (zh) 用以預防或治療癌症或發炎的包含新穎腸膜明串珠菌菌株之組成物及使用其預防或治療癌症或發炎的方法
TWI847369B (zh) 新穎腸膜明串珠菌菌株
JP6088648B2 (ja) 貪食細胞へ物質を送達する担体
JP4308350B2 (ja) シイタケ菌糸体抽出物を含有するlak活性スクリーニング物質およびそれを用いたlak活性スクリーニング法
EP4591872A1 (en) Composition comprising lactobacillus plantarum strain for improving intestinal metabolite composition
KR20230121536A (ko) 락토바실러스 플란타룸 균주 및 항암제를 포함하는 병용 요법을 이용한 암 예방 또는 치료용 조성물
JP2025529567A (ja) ラクトバチルス・プランタルム菌株を含む腸内代謝産物組成を改善するための組成物
JP5761679B2 (ja) パパイア発酵物を有効成分とする末梢血単核球細胞の活性調節用組成物
KR20240123764A (ko) 락토바실러스 플란타룸 균주 및 면역세포의 병용 요법을 이용한 암 예방 또는 치료용 조성물
KR20240040601A (ko) 락토바실러스 플란타룸 균주를 포함하는 장내 대사산물 조성의 개선을 위한 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230905